25 € Neukundenbonus + 1 Aktie gratis. Hol Dir jetzt Dein finanzen.net ZERO-Depot!

Bristol-Myers Squibb Aktie

NeuKaufen Kaufen Verkaufen Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

41,21 EUR -0,41 EUR -0,99 %

23.05.2025

STU

46,87 USD -0,14 USD -0,30 %

nachbörslich23.05.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.84,20 Mrd. EUR

Div. Rendite4,28%

WKN850501

ISINUS1101221083

SymbolBMY

Bristol-Myers Squibb Aktien News

Sortieren:Datum Meistgelesen

22.05.24PR NewswireNeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

29.04.24PR NewswireRepertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

WerbungBristol-Myers Squibb-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

12.04.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

28.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

19.03.24PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY

14.12.23PR NewswireTerray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb

07.12.23MyDividendsBristol-Myers Squibb erhöht die Dividende das 15. Jahr in Folge

28.11.23PR NewswireAvidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology

30.10.23PR NewswireKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory...

06.10.23PR NewswireParadigm and Bristol Myers Squibb collaborate to build a new model for clinical trials

21.09.23MyDividendsBristol-Myers Squibb meldet Dividende

18.09.23PR NewswireSamsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

28.08.23PR NewswireCellares gibt bekannt, dass sich Bristol Myers Squibb dem Technology Adoption Partnership Programm angeschlossen hat, um die automatisierte Herstellung der CAR-T-Zelltherapie auf der Cell Shuttle-...

28.08.23PR NewswireCellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

28.06.23PR NewswireK36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic T...

15.06.23MyDividendsBristol-Myers Squibb kündigt Dividende an

06.03.23MyDividendsBristol-Myers Squibb gibt Dividende bekannt

09.12.22MyDividendsBristol-Myers Squibb steigert die Dividende

29.11.22PR NewswireEnvisagenics Announces Research Collaboration with Bristol Myers Squibb

10.11.22PR NewswireHealth Canada Approves Camzyos™ (mavacamten capsules) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

09.11.22RSSForm 4 14272

27.10.22PR NewswireObsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

26.10.22RSSForm 8-K 14272

22.09.22RSSStatement of changes in beneficial ownership of securities

15.09.22MyDividendsBristol-Myers Squibb schüttet Quartalsdividende aus

23.08.22PR NewswireHealth Canada Approves OPDIVO® (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Adult Patients with Resectable Non-Small Cell Lung Cancer

16.08.22RSSTender offer statement by Third Party

09.08.22RSSTender offer statement by Third Party

19.07.22RSSTender offer statement by Third Party

01.07.22RSSTender offer statement by Third Party

28.06.22PR NewswireHealth Canada Approves OPDIVO® (nivolumab) as Monotherapy for the Adjuvant treatment of Adults with Urothelial Carcinoma (UC) at High Risk of Recurrence after Undergoing Radical Resection of UC

17.06.22RSSTender offer statement by Third Party

16.06.22RSSAnnual report of employee stock purchase, savings and similar plans

03.06.22RSSWritten communication relating to an issuer or third party

Bristol-Myers Squibb News

Bristol-Myers Squibb News: auf dieser Seite finden Sie alle Bristol-Myers Squibb News und Nachrichten zur Bristol-Myers Squibb Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Bristol-Myers Squibb News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Bristol-Myers Squibb News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.